2017年8月24日,湖南昭泰医疗集团完全拥有自主知识产权的car-t细胞治疗癌症技术的一期临床数据成果,已被全球白血病
a novel generation 1928zt2 car t cells induce remission in e
cd215+ myeloid cells respond to interleukin 15 stimulation a
defined, serumfeeder-free conditions for expansion and drug
incorporation of functional elements enhances the antitumor
Defined, serumfeeder-free conditions for expansion and drug screening of primary B-acute lymphoblastic leukemia